23
Jan

Palo Alto, CA’s Carbylan Therapeutics has set terms for an IPO worth $75 million at its midpoint, working to get a treatment for osteoarthritis pain through late-stage development.

…read more

Source: Osteoarthritis biotech Carbylan swings for a $75M IPO

    

0 No comments